PL367414A1 - Kombinacja inhibitora PDE i antagonisty receptoraleukotrienowego - Google Patents

Kombinacja inhibitora PDE i antagonisty receptoraleukotrienowego

Info

Publication number
PL367414A1
PL367414A1 PL02367414A PL36741402A PL367414A1 PL 367414 A1 PL367414 A1 PL 367414A1 PL 02367414 A PL02367414 A PL 02367414A PL 36741402 A PL36741402 A PL 36741402A PL 367414 A1 PL367414 A1 PL 367414A1
Authority
PL
Poland
Prior art keywords
combination
leukotriene receptor
receptor antagonist
pde inhibitor
leukotriene
Prior art date
Application number
PL02367414A
Other languages
English (en)
Other versions
PL205927B1 (pl
Inventor
Rolf Beume
Daniela Bundschuh
Christian Weimar
Stefan-Lutz Wollin
Original Assignee
Altana Pharma Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Altana Pharma Ag filed Critical Altana Pharma Ag
Publication of PL367414A1 publication Critical patent/PL367414A1/pl
Publication of PL205927B1 publication Critical patent/PL205927B1/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
PL367414A 2001-09-19 2002-09-17 Kompozycja farmaceutyczna zawierająca inhibitor PDE - roflumilast i antagonistę receptora leukotrienowego - montelukast, sposób wytwarzania tej kompozycji, produkt farmaceutyczny i zestaw zawierający te związki oraz zastosowanie kompozycji i produktu farmaceutycznego PL205927B1 (pl)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP01000474 2001-09-19

Publications (2)

Publication Number Publication Date
PL367414A1 true PL367414A1 (pl) 2005-02-21
PL205927B1 PL205927B1 (pl) 2010-06-30

Family

ID=8176066

Family Applications (1)

Application Number Title Priority Date Filing Date
PL367414A PL205927B1 (pl) 2001-09-19 2002-09-17 Kompozycja farmaceutyczna zawierająca inhibitor PDE - roflumilast i antagonistę receptora leukotrienowego - montelukast, sposób wytwarzania tej kompozycji, produkt farmaceutyczny i zestaw zawierający te związki oraz zastosowanie kompozycji i produktu farmaceutycznego

Country Status (25)

Country Link
US (1) US20050014762A1 (pl)
EP (1) EP1429843B1 (pl)
JP (1) JP2005505570A (pl)
KR (1) KR20040044946A (pl)
CN (1) CN100346831C (pl)
AT (1) ATE349243T1 (pl)
BR (1) BR0212582A (pl)
CA (1) CA2460442A1 (pl)
CO (1) CO5560584A2 (pl)
CY (1) CY1106365T1 (pl)
DE (1) DE60217139T2 (pl)
DK (1) DK1429843T3 (pl)
EA (1) EA007736B1 (pl)
ES (1) ES2279004T3 (pl)
HU (1) HUP0500078A3 (pl)
IL (2) IL160272A0 (pl)
MA (1) MA27136A1 (pl)
MX (1) MXPA04002560A (pl)
NO (1) NO331885B1 (pl)
NZ (1) NZ532279A (pl)
PL (1) PL205927B1 (pl)
PT (1) PT1429843E (pl)
SI (1) SI1429843T1 (pl)
WO (1) WO2003024488A2 (pl)
ZA (1) ZA200402653B (pl)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0719518D0 (en) * 2007-10-05 2007-11-14 Therapeutics Ltd E Therapy
KR20100072295A (ko) * 2007-10-25 2010-06-30 머크 프로스트 캐나다 리미티드 병용 요법
WO2012168907A1 (en) 2011-06-10 2012-12-13 Glenmark Pharmaceuticals Sa Pharmaceutical composition comprising revamilast and montelukast or zafirlukast
WO2014012954A1 (en) 2012-07-18 2014-01-23 Takeda Gmbh Treatment of partly controlled or uncontrolled severe asthma
BR112015019276A2 (pt) 2013-02-19 2017-07-18 Pfizer compostos de azabenzimidazol como inibidores de isoenzimas de pde4 para o tratamento de distúrbios do snc e outros distúrbios
WO2015063669A1 (en) 2013-10-30 2015-05-07 Wockhardt Limited Pharmaceutical compositions comprising combination of roflumilast and acebrophylline or pharmaceutically acceptable salts thereof
WO2015110394A1 (en) 2014-01-22 2015-07-30 Takeda Gmbh Treatment of partly controlled or uncontrolled severe asthma with a pde4 inhibitor (and in combination with a leukotriene modifier)
WO2016012896A1 (en) 2014-07-24 2016-01-28 Pfizer Inc. Pyrazolopyrimidine compounds
MD20170011A2 (ro) 2014-08-06 2017-08-31 Pfizer Inc. Compuşi imidazopiridazinici

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY121142A (en) * 1999-02-23 2005-12-30 Smithkline Beecham Corp Controlled release formulation for treating copd
CA2715683A1 (en) * 1999-08-21 2001-03-01 Nycomed Gmbh Synergistic combination
MY134008A (en) * 1999-12-22 2007-11-30 Merck Frosst Canada Inc Subtituted 8-arylquinoline phospohodiestrase-4 inhibitors
CZ20022410A3 (cs) * 2000-01-31 2003-08-13 Pfizer Products Inc. Benzoanelované heterocyklylové deriváty nikotinamidu užitečné jako selektivní inhibitory isozymů PDE4
MY123585A (en) * 2000-03-23 2006-05-31 Merck Canada Inc Tri-aryl-substituted-ethane pde4 inhibitors.
EP1289961A1 (en) * 2000-05-25 2003-03-12 Merck Frosst Canada & Co. Fluoroalkoxy-substituted benzamide dichloropyridinyl n-oxide pde4 inhibitor

Also Published As

Publication number Publication date
CN1655846A (zh) 2005-08-17
PL205927B1 (pl) 2010-06-30
JP2005505570A (ja) 2005-02-24
ZA200402653B (en) 2005-02-14
EA007736B1 (ru) 2006-12-29
NO20041595L (no) 2004-06-16
CA2460442A1 (en) 2003-03-27
WO2003024488A3 (en) 2003-09-04
HUP0500078A3 (en) 2010-07-28
IL160272A (en) 2008-03-20
NO331885B1 (no) 2012-04-30
WO2003024488A2 (en) 2003-03-27
HUP0500078A2 (hu) 2005-04-28
EA200400416A1 (ru) 2004-12-30
DK1429843T3 (da) 2007-04-30
MA27136A1 (fr) 2005-01-03
MXPA04002560A (es) 2004-05-31
CY1106365T1 (el) 2011-10-12
DE60217139T2 (de) 2007-10-04
IL160272A0 (en) 2004-07-25
BR0212582A (pt) 2004-10-13
PT1429843E (pt) 2007-03-30
CN100346831C (zh) 2007-11-07
SI1429843T1 (sl) 2007-06-30
ES2279004T3 (es) 2007-08-16
CO5560584A2 (es) 2005-09-30
HK1066752A1 (en) 2005-04-01
US20050014762A1 (en) 2005-01-20
EP1429843A2 (en) 2004-06-23
EP1429843B1 (en) 2006-12-27
DE60217139D1 (de) 2007-02-08
KR20040044946A (ko) 2004-05-31
ATE349243T1 (de) 2007-01-15
NZ532279A (en) 2006-02-24

Similar Documents

Publication Publication Date Title
HUP0302476A3 (en) Use of acetylcholinesterase inhibitors and gabaainverse agonists for the treatment of cognitive disorders and for preparation of pharmaceutical compositins
HUP0600103A2 (en) Co-administration of melanocortin receptor agonist and phosphodiesterase inhibitor for treatment of cyclic-amp associated disorders
MXPA04003668A (es) Inhibidores de fosfodiesteresa de tipo 4 y usos de los mismos.
EP1827468A4 (en) LEUPROLID ACETATE AND ACETYLCHOLINESTERASE INHIBITORS OR NMDA RECEPTOR ANTAGONISTS FOR THE TREATMENT OF ALZHEIMER DISEASE
CY1106365T1 (el) Συνδυασμος ενος αναστολεα pde και ενος ανταγωνιστη υποδοχεων λευκοτριενιου
CY1106927T1 (el) Φαρμακευτικη συνθεση ενος pde4 ή pde3/4 αναστολεα και ανταγωνιστη υποδοχεα ισταμινης
WO2002081728A3 (en) Quinoline inhibitors of hyak1 and hyak3 kinases
IL198759A (en) Use of 3gal receptor antagonists to prepare medications to treat depression and / or anxiety
WO2002072093A3 (en) Use of dual h3/m2 antagonists with a bipiperidinic structure in the treatment of cognition deficit disorders
ID29818A (id) Penggunaan antagonis reseptor angiotensin ii untuk mengobati infarksi miokardial
BR0000486A (pt) Antagonistas do neuropeptìdeo y
PL369736A1 (pl) Nowe kompozycje leków na bazie antycholinergików oraz inhibitorów kinazy EGFR
NO20033634L (no) GLyT-1-inhibitorer
MXPA03009506A (es) USO DE COMPUESTOS ELIMINADORES DE RADICALES PARA EL TRATAMIENTO Y PREVENCIoN DE TRASTORNOS DE LA MICRO-CIRCULACION DEPENDIENTES DE NO.
HK1057488A (en) Co-administration of melanocortin receptor agonist and phosphodiesterase inhibitor for treatment of cyclic-amp associated disorders
MY139844A (en) 1,2,4-triaminobenzene derivatives and their uses thereof for the prevention, treatment and/or inhibition of disorders of the central nervous system